Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 3

Когнитивные нарушения и синдром хронической усталости
Н.В. Пизова, А.В. Пизов

References

1. Brurberg KG, Fønhus MS, Larun L, Flottorp S, Malterud K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review. BMJ Open 2014 Feb;4(2):e003973.
2. Carruthers BM, Jain AK, De Merileir KL, Peterson DL, Klimas NG, Lehrner AM. Myalgic encephalomyelitis/chronic fatigue syndrome; clinical working case definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome 2003 Dec;11(1):7-115.
3. Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS, Speight N, Stewart JM, Vallings R, Rowe KS. Myalgic encephalomyelitis/chronic fatigue syndrome diagnosis and management in young people: a primer. Frontiers in Pediatrics 2017 Jun;5:121.
4. Reeves WC, Jones JF, Maloney E, Heim C, Hoaglin DC, Boneva RS, Morrissey M, Devlin R. Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia. Population Health Metrics 2007 Jun;5:1-10.
5. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. Washington, DC: National Academies Press; 2015. doi: 10.17226/19012.
6. Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review. Diagnostics (Basel, Switzerland) 2019 Aug;9(3):91.
7. Bested AC, Marshall LM. Review of myalgic encephalomyelitis/chronic fatigue syndrome: an evidence-based approach to diagnosis and management by clinicians. Reviews on Environmental Health 2015;30(4):223-49.
8. Nacul L, Kingdon CC, Bowman EW, Curran H, Lacerda EM. Differing case definitions point to the need for an accurate diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue: Biomedicine, Health & Behavior 2017;5(1):1-4.
9. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B. Chronic fatigue syndrome, the immune system and viral infection. Brain, Behavior, and Immunity 2012 Jan;26(1):24-31.
10. Komaroff AL, Buchwald DS. Chronic fatigue syndrome: an update. Annual Review of Medicine 1998;49:1-13.
11. Mariman A, Delesie L, Tobback E, Hanoulle I, Sermijn E, Vermeir P, Pevernagie D, Vogelaers D. Undiagnosed and comorbid disorders in patients with presumed chronic fatigue syndrome. Journal of Psychosomatic Research 2013 Nov;75(5):491-6.
12. Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. The American Journal of Hospice & Palliative Care 2014 Aug;31(5):562-75.
13. Bjørklund G, Dadar M, Pen JJ, Chirumbolo S, Aaseth J. Chronic fatigue syndrome (CFS): suggestions for a nutritional treatment in the therapeutic approach. Biomedicine & Pharmacotherapy 2019 Jan;109:1000-7.
14. Morrow GR. Cancer-related fatigue: causes, consequences, and management. The Oncologist 2007;12(Suppl 1):1-3.
15. Faro M, Sàez-Francás N, Castro-Marrero J, Aliste L, Fernández de Sevilla T, Alegre J. Gender differences in chronic fatigue syndrome. Reumatología Clínica 2016 Mar-Apr;12(2):72-7.
16. Ter Wolbeek M, van Doornen LJ, Kavelaars A, van de Putte EM, Schedlowski M, Heijnen CJ. Longitudinal analysis of pro- and anti-inflammatory cytokine production in severely fatigued adolescents. Brain, Behavior, and Immunity 2007 Nov;21(8):1063-74.
17. Kruesi MJ, Dale J, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. The Journal of Clinical Psychiatry 1989 Feb;50(2):53-6.
18. Taerk GS, Toner BB, Salit IE, Garfinkel PE, Ozersky S. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). The International Journal of Psychiatry in Medicine 1987;17(1):49-56.
19. Cope H, Mann A, David A, Pelosi A. Predictors of chronic "postviral" fatigue. The Lancet 1994 Sep;344(8926):864-8.
20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020 Feb;395(10223):497-506.
21. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Mar;323(11):1061-9.
22. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020 Feb;368:m606.
23. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 Jul;75(7):1730-41.
24. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, Chen G, Zhang Y, Li D, Li J, Lian H, Niu S, Zhang L, Zhang J. Characteristics of COVID-19 infection in Beijing. The Journal of Infection 2020 Apr;80(4):401-6.
25. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. Journal of Medical Virology 2020 Oct;92(10):1902-14.
26. Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J, Zhang J, Zhao C. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Family Medicine and Community Health 2020 Apr;8(2):e000406.
27. Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. New Scientist 2020 Apr;246(3278):10-11.
28. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurology 2011 Mar;11:37.
29. Lam MHB, Wing YK, Yu MWM, Leung CM, Ma RCW, Kong APS, So WY, Fong SYY, Lam SP. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Archives of Internal Medicine 2009 Dec;169(22):2142-7.
30. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O’Connor L, Leavy D, O’Brien K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Cheallaigh CN, Nadarajan P, McLaughlin AM, Bourke NM, Bergin C, O’Farrelly C, Bannan C, Conlon N. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020 Nov;15(11):e0240784.
31. Komaroff A. The tragedy of the post-COVID “Long Haulers”. Harvard Health Letter. 2018. Available from: https://www.health.harvard.edu/blog/the-tragedy-of-the-post-covid-long-haulers-2020101521173 Accessed 2021 Sep 17.
32. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ 2020 Aug;370:m3026.
33. Huang C, Huang L, Wang Y, Xia Li, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021 Jan;397(10270):220-32.
34. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 Aug;38:101019.
35. Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Zoller T, Steinbeis F, Haffke M, Rudolf G, Heidecker B, Volk HD, Skurk C, Paul F, Bellmann-Strobl J, Scheibenbogen C. Chronic COVID-19 syndrome and chronic fatigue syndrome (ME/CFS) following the first pandemic wave in Germany – a first analysis of a prospective observational study. medRxiv 2021 Feb. doi: 10.1101/2021.02.06.21249256.
36. Menon R, Larner AJ. Use of cognitive screening instruments in primary care: the impact of national dementia directives (NICE/SCIE, National Dementia Strategy). Family Practice 2011 Jun;28(3):272-6.
37. Larner A. Impact of the National Dementia Strategy in a neurology-led memory clinic: 5-year data. Clinical Medicine (London, England) 2014 Apr;14(2):216.
38. Bell S, Harkness K, Dickson JM, Blackburn D. A diagnosis for £55: what is the cost of government initiatives in dementia case finding. Age & Ageing 2015 Mar;44(2):344-5.
39. Teodoro T, Edwards MJ, Isaacs JD. A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. Journal of Neurology, Neurosurgery and Psychiatry 2018 Dec;89(12):1308-19.
40. Pennington C, Hayre A, Newson M, Coulthard E. Functional cognitive disorder: a common cause of subjective cognitive symptoms. Journal of Alzheimers Disease 2015 Sep;48 (Suppl 1):S19-24.
41. Stone J, Pal S, Blackburn D, Reuber M, Thekkumpurath P, Carson A. Functional (psychogenic) cognitive disorders: a perspective from the neurology clinic. Journal of Alzheimers Disease 2015 Sep;48(Suppl 1):S5-17.
42. Delis DC, Wetter SR. Cogniform disorder and cogniform condition: proposed diagnoses for excessive cognitive symptoms. Archives of Clinical Neuropsychology 2007 Jun;22(5):589-604.
43. Schmidtke K, Pohlmann S, Metternich B. The syndrome of functional memory disorder: definition, etiology, and natural course. The American Journal of Geriatric Psychiatry 2008 Dec;16(12):981-8.
44. Griem J, Stone J, Carson A, Kopelman MD. Psychologic/functional forms of memory disorder. Handbook of Clinical Neurology 2016;139:407-17.
45. Glass JM. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control impairments. Rheumatic Disease Clinics of North America 2009 May;35(2):299-311.
46. Cvejic E, Birch RC, Vollmer-Conna U. Cognitive dysfunction in chronic fatigue syndrome: a review of recent evidence. Current Rheumatology Reports 2016 May;18(5):24.
47. Fiedler N, Kipen HM, DeLuca J, Kelly-McNeil K, Natelson B. A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosomatic Medicine 1996 Jan-Feb;58(1):38-49.
48. McDonald E, Cope H, David A. Cognitive impairment in patients with chronic fatigue: a preliminary study. Journal of Neurology, Neurosurgery and Psychiatry 1993 Jul;56(7):812-5.
49. Smith AP, Behan PO, Bell W, Millar K, Bakheit M. Behavioural problems associated with the chronic fatigue syndrome. British Journal of Psychology 1993 Aug;84(Pt 3):411-23.
50. Vercoulen JH, Bazelmans E, Swanink CM, Galama JM, Fennis JF, van der Meer JW, Bleijenberg G. Evaluating neuropsychological impairment in chronic fatigue syndrome. Journal of Clinical and Experimental Neuropsychology 1998 Apr;20(2):144-56.
51. Schmaling KB, Betterton KL. Neurocognitive complaints and functional status among patients with chronic fatigue syndrome and fibromyalgia. Quality of Life Research 2016 May;25(5):1257-63.
52. Lakein DA, Fantie BD, Grafman J, Ross S, O’Fallon A, Dale J, Straus SE. Patients with chronic fatigue syndrome and accurate feeling-of-knowing judgments. Journal of Clinical Psychology 1997 Nov;53(7):635-45.
53. Michiels V, de Gucht V, Cluydts R, Fischler B. Attention and information processing efficiency in patients with chronic fatigue syndrome. Journal of Clinical and Experimental Neuropsychology 1999 Oct;21(5):709-29.
54. Thomas M, Smith A. An investigation into the cognitive deficits associated with chronic fatigue syndrome. The Open Neurology Journal 2009 Feb;3:13-23.
55. Ickmans K, Meeus M, Kos D, Clarys P, Meersdom G, Lambrecht L, Pattyn N, Nijs J. Cognitive performance is of clinical importance, but is unrelated to pain severity in women with chronic fatigue syndrome. Clinical Rheumatology 2013 Oct;32(10):1475-85.
56. Joyce E, Blumenthal S, Wessely S. Memory, attention, and executive function in chronic fatigue syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1996 May;60(5):495-503.
57. Metzger FA, Denney DR. Perception of cognitive performance in patients with chronic fatigue syndrome. Annals of Behavioral Medicine 2002 Spring;24(2):106-12.
58. Schmaling KB, Lewis DH, Fiedelak JI, Mahurin R, Buchwald DS. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosomatic Medicine 2003 Jan-Feb;65(1):129-36.
59. Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. Journal of Clinical Rheumatology 2004 Apr;10(2):53-8.
60. Cope H, Pernet A, Kendall B, David A. Cognitive functioning and magnetic resonance imaging in chronic fatigue. The British Journal of Psychiatry 1995 Jul;167(1):86-94.
61. Attree EA, Arroll MA, Dancey CP, Griffith C, Bansal AS. Psychosocial factors involved in memory and cognitive failures in people with myalgic encephalomyelitis/chronic fatigue syndrome. Psychology Research and Behavior Management 2014 Feb;7:67-76.
62. Gotts ZM, Ellis JG, Deary V, Barclay N, Newton JL. The association between daytime napping and cognitive functioning in chronic fatigue syndrome. PLoS One 2015 Jan;10(1):e0117136.
63. Dobbs BM, Dobbs AR, Kiss I. Working memory deficits associated with chronic fatigue syndrome. Journal of the International Neuropsychological Society 2001 Mar;7(3):285-93.
64. Deluca J, Christodoulou C, Diamond BJ, Rosenstein ED, Kramer N, Natelson BH. Working memory deficits in chronic fatigue syndrome: differentiating between speed and accuracy of information processing. Journal of the International Neuropsychological Society 2004 Jan;10(1):101-9.
65. Marshall PS, Forstot M, Callies A, Peterson PK, Schenck CH. Cognitive slowing and working memory difficulties in chronic fatigue syndrome. Psychosomatic Medicine 1997 Jan-Feb;59(1):58-66.
66. Sandman CA, Barron JL, Nackoul K, Goldstein J, Fidler F. Memory deficits associated with chronic fatigue immune dysfunction syndrome. Biological Psychiatry 1993 Apr-May;33(8-9):618-23.
67. Riccio M, Thompson C, Wilson B, Morgan DJ, Lant AF. Neuropsychological and psychiatric abnormalities in myalgic encephalomyelitis: a preliminary report. British Journal of Clinical Psychology 1992 Feb;31(1):111-20.
68. Neu D, Kajosch H, Peigneux P, Verbanck P, Linkowski P, Le Bon O. Cognitive impairment in fatigue and sleepiness associated conditions. Psychiatry Research 2011 Aug;189(1):128-34.
69. Claypoole KH, Noonan C, Mahurin RK, Goldberg J, Erickson T, Buchwald D. A twin study of cognitive function in chronic fatigue syndrome: the effects of sudden illness onset. Neuropsychology 2007 Jul;21(4):507-13.
70. Michiels V, Cluydts R, Fischler B, Hoffmann G, Le Bon O, De Meirleir K. Cognitive functioning in patients with chronic fatigue syndrome. Journal of Clinical and Experimental Neuropsychology 1996;18:666-77.
71. Constant EL, Adam S, Gillain B, Lambert M, Masquelier E, Seron X. Cognitive deficits in patients with chronic fatigue syndrome compared to those with major depressive disorder and healthy controls. Clinical Neurology and Neurosurgery 2011 May;113(4):295-302.
72. Wearden A, Appleby L. Cognitive performance and complaints of cognitive impairment in chronic fatigue syndrome (CFS). Psychological Medicine 1997 Jan;27(1):81-90.
73. Grafman J, Schwartz V, Dale JK, Scheffers M, Houser C, Straus SE. Analysis of neuropsychological functioning in patients with chronic fatigue syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1993 Jun;56(6):684-9.
74. Gaudino EA, Coyle PK, Krupp LB. Post-Lyme syndrome and chronic fatigue syndrome. Neuropsychiatric similarities and differences. Archives of Neurology 1997 Nov;54(11):1372-6.
75. Tiersky LA, Matheis RJ, Deluca J, Lange G, Natelson BH. Functional status, neuropsychological functioning, and mood in chronic fatigue syndrome (CFS): relationship to psychiatric disorder. The Journal of Nervous and Mental Disease 2003 May;191(5):324-31.
76. Busichio K, Tiersky LA, Deluca J, Natelson BH. Neuropsychological deficits in patients with chronic fatigue syndrome. Journal of the International Neuropsychological Society 2004 Mar;10(2):278-85.
77. Claypoole K, Mahurin R, Fischer ME, Goldberg J, Schmaling KB, Schoene RB, Ashton S, Buchwald D. Cognitive compromise following exercise in monozygotic twins discordant for chronic fatigue syndrome: fact or artifact? Applied Neuropsychology 2001;8(1):31-40.
78. Lawrie SM, MacHale SM, Cavanagh JT, O’Carroll RE, Goodwin GM. The difference in patterns of motor and cognitive function in chronic fatigue syndrome and severe depressive illness. Psychological Medicine 2000 Mar;30(2):433-42.
79. Marcel B, Komaroff AL, Fagioli LR, Kornish RJ 2nd, Albert MS. Cognitive deficits in patients with chronic fatigue syndrome. Biological Psychiatry 1996 Sep;40(6):535-41.
80. Daly E, Komaroff AL, Bloomingdale K, Wilson S, Albert MS. Neuropsychological function in patients with chronic fatigue syndrome, multiple sclerosis, and depression. Applied Neuropsychology 2001;8(1):12-22.
81. Blackwood SK, MacHale SM, Power MJ, Goodwin GM, Lawrie SM. Effects of exercise on cognitive and motor function in chronic fatigue syndrome and depression. Journal of Neurology, Neurosurgery and Psychiatry 1998 Oct;65(4):541-6.
82. Ross S, Fantie B, Straus SF, Grafman J. Divided attention deficits in patients with chronic fatigue syndrome. Applied Neuropsychology 2001;8(1):4-11.
83. Santamarina-Perez P, Eiroa-Orosa FJ, Freniche V, Moreno-Mayos A, Alegre J, Saez N, Jacas C. Length of illness does not predict cognitive dysfunction in chronic fatigue syndrome. Applied Neuropsychology 2011 Jul;18(3):216-22.
84. Inglis JE, Lin PJ, Kerns SL, Kleckner IR, Kleckner AS, Castillo DA, Mustian KM, Peppone LJ. Nutritional interventions for treating cancer-related fatigue: a qualitative review. Nutrition and Cancer 2019;71(1):21-40.
85. Collatz A, Johnston SC, Staines DR, Marshall-Gradisnik SM. A systematic review of drug therapies for chronic fatigue syndrome/myalgic encephalomyelitis. Clinical Therapeutics 2016 Jun;38(6):1263-71.e9.
86. Olson LG, Ambrogetti A, Sutherland DC. A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics 2003 Jun-Feb;44(1):38-43.
87. Hickie I. Nefazodone for patients with chronic fatigue syndrome. Australian & New Zealand Journal of Psychiatry 1999 Apr;3(2):278-80.
88. Mitchell WM. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Review of Clinical Pharmacology 2016 Jun;9(6):755-70.
89. Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell WM. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One 2012;7(3):e31334.
90. Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A, Neri S, Vacante M, Cammalleri L, Motta M. Acetyl l-carnitine (ALC) treatment in elderly patients with fatigue. Archives of Gerontology and Geriatrics 2008 Mar-Apr;46(2):181-90.
91. Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clinical Infectious Diseases 2003 May;36(9):e100-6.
92. Montenegro L, Turnaturi R, Parenti C, Pasquinucci L. Idebenone: novel strategies to improve its systemic and local efficacy. Nanomaterials (Basel, Switzerland) 2018 Feb;8(2):87.
93. Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. Journal of Neurology 2009 Mar;256(Suppl 1):25-30.
94. El-Hattab AW, Zarante AM, Almannai M, Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Molecular Genetics and Metabolism 2017 Nov;122(3):1-9.
95. Geromel V, Darin N, Chrétien D, Bénit P, DeLonlay P, Rötig A, Munnich A, Rustin P. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Molecular Genetics and Metabolism 2002 Sep-Oct;77(1-2):21-30.
96. Erb M, Hoffmann-Enger B, Deppe H, Soeberdt M, Haefeli RH, Rummey C, Feurer A, Gueven N. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. PLoS One 2012;7(4):e36153.
97. Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619). Japanese Journal of Pharmacology 1984 Jun;35(2):196-8.
98. Jaber S, Polster BM. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier? Journal of Bioenergetic and Biomembrans 2015 Apr;47(1-2):111-8.
99. Gueven N, Ravishankar P, Eri R, Rybalka E. Idebenone: when an antioxidant is not an antioxidant. Redox Biology 2021 Jan;38:101812.
100. Zhang ZW, Xu XC, Liu T, Yuan S. Mitochondrion-permeable antioxidants to treat ROS-burst-mediated acute diseases. Oxidative Medicine and Cellular Longevity 2016;2016:6859523.
101. Kumar A, Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Frontiers in Pharmacology 2015 Sep;6:206.
102. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. European Journal of Neuroscience 1999 Jan;11(1):83-90.
103. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. In: Alzheimer’s disease – from basic research to clinical applications. Gertz HJ, Arendt T, editors. Journal of Neural Transmission. Supplementum. Vol. 54. Vienna: Springer; 1998: 301-10.
104. Nappi G, Bono G, Merlo P, Denaro A, Proietti R, Martucci N, Fioravanti M. Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Archives of Gerontology and Geriatrics 1992 Nov-Dec;15(3):261-9.
105. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denaro M, Marigliano V, Tammaro AE, Fioravanti M. Idebenone in senile dementia of Alzheimer type: a multicentre study. Archives of Gerontology and Geriatrics 1992 Nov-Dec;15(3):249-60.
106. Bergamasco B, Scarzella L, La CP. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Functional Neurology 1994 May-Jun;9(3):161-8.
107. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36(2):73-82.
108. Gutzmann H, Kühl KP, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002 Jan;35(1):12-8.
109. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 2003;61:1498-502.
110. Lin P, Liu J, Ren M, Ji K, Li L, Zhang B, Gong Y, Yan C. Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3β/β-catenin signalling pathways. Biochemical and Biophysical Research Communications 2015 Sep;465(3):548-55.
111. Jiang W, Geng H, Lv X, Ma J, Liu F, Lin P. Idebenone protects against atherosclerosis in apolipoprotein E-deficient mice via activation of the Sirt3-SOD2-mtROS pathway. Cardiovascular Drugs & Therapy 2020 Jun 17. doi: 10.1007/s10557-020-07018-5. Online ahead of print.
112. Kakihana M, Yamazaki N, Nagaoka A. Effects of idebenone on the levels acetylcholine, choline, free fatty acids, and energy metabolites in the brain of rats with cerebral ischemia. Archives of Gerontology and Geriatrics 1989 May;8(3):247-56.
113. Suno M, Terashita Z, Nagaoka A. Ingibition of platelet aggregation by idebenone and mechanism of the ingibition. Archives Gerontology and Geriatrics 1989 May;8(3):313-21.
114. Kutz K, Drewe J, Vankan P. Pharmacokinetic properties and metabolism of idebenone. Journal of Neurology 2009 Mar;256(Suppl 1):31-5.
115. Noben® Available from: https://www.rlsnet.ru/tn_index_id_28545.htm Accessed 2021 Sep 17.
116. Voronkova KV, Meleshkov MN. Noben (idebenone) in the treatment of dementia and memory impairment without dementia. SS Korsakov Journal of Neurology and Psychiatry 2008;108(4):27-32 (In Russian).
117. Kapustenskaya ZhI, Shprach VV, Zaytseva OA. Affective and cognitive disorders in persons of elderly and senile age. Bulletin of the Eastern-Siberian Scientific Center of Siberian Branch of Russian Academy of Medical Sciences 2010;2:72-4 (In Russian).
118. Rachin AP, Averchenkova AA. Idebenon (noben) – from theory to practice. SS Korsakov Journal of Neurology and Psychiatry 2011;111(5):81-4 (In Russian).
119. Bochkarev VK, Fayzulloyev AZ, Borodin VI, Avedisova AS. Psychophysiological characteristics of noben action. Psychiatry and Psychopharmacotherapy 2004;6(4):197-9 (In Russian).
120. Muzychenko AP, Krasnoslobodtseva LA, Lubsanova SV. Clinical effect of noben in organic emotionally labile (asthenic) disorder. Atmosphere. Nervous Diseases 2008;1:15-7 (In Russian).
121. Castro-Marrero J, Sáez-Francás N, Santillo D, Alegre J. Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome. The British Journal of Pharmacology 2017 Mar;174(5):345-69.
122. Blitshteyn S, Chopra P. Chronic fatigue syndrome: from chronic fatigue to more specific syndromes. European Neurology 2018;80(1-2):73-7.
123. Craig C. Mitoprotective dietary approaches for myalgic encephalomyelitis/chronic fatigue syndrome: caloric restriction, fasting, and ketogenic diets. Medical Hypotheses 2015 Nov;85(5):690-3.
124. Comhaire F. Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate: an open-label, proof-of-principle pilot trial. Medical Hypotheses 2018 May;114:45-8.
125. Kumar A, Garg R. Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. Fundamental & Clinical Pharmacology 2009 Feb;23(1):89-95.
126. Corbitt M, Campagnolo N, Staines D, Marshall-Gradisnik S. A systematic review of probiotic interventions for gastrointestinal symptoms and irritable bowel syndrome in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Probiotics and Antimicrobial Proteins 2018 Sep;10(3):466-77.
127. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, Baber HL, Burgess M, Clark LV, Cox DL, Bavinton J, Angus BJ, Murphy G, Murphy M, O’Dowd H, Wilks D, McCrone P, Chalder T, Sharpe M; PACE trial management group. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet 2011 May;377(9768):823-36.
128. Wilshire CE, Kindlon T. Response: Sharpe, Goldsmith and Chalder fail to restore confidence in the PACE trial findings. BMC Psychology 2019 Mar;7(1):19.
129. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Prognosis in chronic fatigue syndrome: a prospective study on the natural course. Journal of Neurology, Neurosurgery and Psychiatry 1996 May;60(5):489-94.
130. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occupational Medicine (Oxford, England) 2005 Jan;55(1):20-31.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]